{"id":"salbutamol-200-g","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Tremors"},{"rate":"5-10%","effect":"Nervousness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to an increase in airway diameter, making it easier to breathe. Salbutamol is often used to treat asthma and COPD symptoms by rapidly relieving bronchospasm.","oneSentence":"Salbutamol is a short-acting β2 adrenergic receptor agonist that works by stimulating the β2 receptors in the lungs, causing bronchodilation and relaxation of bronchial smooth muscle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:43.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relief of bronchospasm in asthma and COPD"},{"name":"Prevention of bronchospasm during exercise"}]},"trialDetails":[{"nctId":"NCT06433908","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-06-04","conditions":"Asthma, Healthy Participants","enrollment":60},{"nctId":"NCT06655012","phase":"NA","title":"Salmeterol Effect on Exercise Performance","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT06654986","phase":"NA","title":"Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT06523257","phase":"","title":"Prevalence of Chronic Obstructive Pulmonary Disease in the Portuguese Population","status":"NOT_YET_RECRUITING","sponsor":"Sociedade Portuguesa de Pneumologia","startDate":"2024-09-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":8589},{"nctId":"NCT05084222","phase":"PHASE4","title":"Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-11-11","conditions":"Asthma","enrollment":180},{"nctId":"NCT03380429","phase":"PHASE4","title":"A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-01-31","conditions":"Asthma","enrollment":437},{"nctId":"NCT03524066","phase":"NA","title":"Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)","status":"COMPLETED","sponsor":"Fraunhofer-Institute of Toxicology and Experimental Medicine","startDate":"2018-04-10","conditions":"Healthy","enrollment":21},{"nctId":"NCT03274791","phase":"","title":"Clinical Features and Airways Inflammation in Never Smokers and Smokers With COPD","status":"COMPLETED","sponsor":"Ministry of Scientific Research, Tunisia","startDate":"2013-09","conditions":"COPD, Airway Obstruction, Inflammation","enrollment":68},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59},{"nctId":"NCT02343419","phase":"NA","title":"Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Methacholine Challenge Test","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2014-11","conditions":"Bronchial Hyperreactivity, Abnormal Respiratory Airway Resistance","enrollment":46},{"nctId":"NCT00669617","phase":"PHASE3","title":"Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":89},{"nctId":"NCT00633919","phase":"PHASE2, PHASE3","title":"Efficacy of SLITone in House Dust Mite Allergic Patients","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2006-07","conditions":"Allergy","enrollment":124},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Salbutamol (200 µg)","genericName":"Salbutamol (200 µg)","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salbutamol is a short-acting β2 adrenergic receptor agonist that works by stimulating the β2 receptors in the lungs, causing bronchodilation and relaxation of bronchial smooth muscle. Used for Relief of bronchospasm in asthma and COPD, Prevention of bronchospasm during exercise.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}